JP2017501227A - アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 - Google Patents

アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 Download PDF

Info

Publication number
JP2017501227A
JP2017501227A JP2016560871A JP2016560871A JP2017501227A JP 2017501227 A JP2017501227 A JP 2017501227A JP 2016560871 A JP2016560871 A JP 2016560871A JP 2016560871 A JP2016560871 A JP 2016560871A JP 2017501227 A JP2017501227 A JP 2017501227A
Authority
JP
Japan
Prior art keywords
acid
alginic acid
residue
molecular weight
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016560871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501227A5 (enExample
Inventor
ガスリー，ウェンデル
ハーン，ゲイリー
Original Assignee
エヴォフェム，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53403777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017501227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エヴォフェム，インク． filed Critical エヴォフェム，インク．
Publication of JP2017501227A publication Critical patent/JP2017501227A/ja
Publication of JP2017501227A5 publication Critical patent/JP2017501227A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
    • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/065—Condom-like devices worn by females
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016560871A 2013-12-19 2014-12-19 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 Pending JP2017501227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361918445P 2013-12-19 2013-12-19
US61/918,445 2013-12-19
PCT/US2014/071664 WO2015095793A1 (en) 2013-12-19 2014-12-19 Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020063444A Division JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2017501227A true JP2017501227A (ja) 2017-01-12
JP2017501227A5 JP2017501227A5 (enExample) 2017-12-07

Family

ID=53403777

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016560871A Pending JP2017501227A (ja) 2013-12-19 2014-12-19 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2020063444A Pending JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2022017393A Pending JP2022070924A (ja) 2013-12-19 2022-02-07 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020063444A Pending JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2022017393A Pending JP2022070924A (ja) 2013-12-19 2022-02-07 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Country Status (15)

Country Link
US (3) US11337989B2 (enExample)
EP (2) EP3082826B1 (enExample)
JP (3) JP2017501227A (enExample)
KR (1) KR102407408B1 (enExample)
CN (2) CN106029078A (enExample)
AU (2) AU2014368971B2 (enExample)
BR (1) BR112016014506B1 (enExample)
DK (1) DK3082826T3 (enExample)
ES (1) ES2790703T3 (enExample)
IL (1) IL246146B2 (enExample)
MX (2) MX2016008023A (enExample)
NZ (1) NZ722215A (enExample)
RU (1) RU2691950C1 (enExample)
WO (1) WO2015095793A1 (enExample)
ZA (1) ZA201604862B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352907B2 (ja) 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法
RU2691950C1 (ru) 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
DE102017110168A1 (de) 2016-05-25 2017-11-30 Samsung Electronics Co., Ltd. Elektronische Vorrichtung mit NFC-Antenne
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
EP3522879A4 (en) * 2016-10-04 2020-06-03 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
EP4422640A4 (en) * 2021-10-28 2025-11-19 Evofem Inc FAST-DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND PREVENTION OF SEXUALLY TRANSMITTED INFECTION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06172375A (ja) * 1992-12-04 1994-06-21 Kibun Food Chemifa Co Ltd オリゴマンヌロン酸を重合度によって分離する方法
WO2001066084A2 (en) * 2000-03-07 2001-09-13 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
WO2004011032A1 (ja) * 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
JP6352907B2 (ja) * 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
JP2009102407A (ja) * 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Ｇリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
JP2004537525A (ja) * 2001-06-11 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド ＰＰＡＲδアゴニストの投与による炎症性疾患の治療法
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) * 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20100069323A1 (en) * 2006-11-10 2010-03-18 Rohto Pharmaceutical Co., Ltd. Composition for application to skin or mucosa
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
AU2008256689A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
CA2721457A1 (en) 2008-04-16 2009-10-22 Cipla Limited Topical combinations comprising an antimycotic agent and an antiviral agent
WO2009155118A1 (en) * 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
EP2440560A1 (en) 2009-06-10 2012-04-18 Ultimorphix Technologies B.v. The succinate of tenofovir disoproxil
EP2704694A4 (en) * 2011-05-02 2014-11-19 Aptalis Pharmatech Inc RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY
AU2012275292B2 (en) 2011-06-28 2015-11-12 Chemo Research, S.L. High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
RU2691950C1 (ru) 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
US9801839B2 (en) 2014-02-28 2017-10-31 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06172375A (ja) * 1992-12-04 1994-06-21 Kibun Food Chemifa Co Ltd オリゴマンヌロン酸を重合度によって分離する方法
WO2001066084A2 (en) * 2000-03-07 2001-09-13 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
WO2004011032A1 (ja) * 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
JP6352907B2 (ja) * 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Biology of mucosally transmitted sexual infection -Translating the basic science into novel HIV inte", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 28(11), JPN7019000398, 11 November 2012 (2012-11-11), pages 1389 - 1396, ISSN: 0004185122 *
"Inhibitory effect of alginic acids on hyaluronidase and on histamine release from mast cells", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 61(6), JPN6019004859, 23 June 1997 (1997-06-23), pages 1030 - 1032, ISSN: 0004185121 *
DEREK H. OWEN. ET AL.: "Factors influencing nonoxynol-9 permeation and bioactivity in cervical mucus", JOURNAL OF CONTROLLED RELEASE, vol. 60, JPN6018025509, 1999, pages 23 - 34, ISSN: 0003977787 *

Also Published As

Publication number Publication date
CN106029078A (zh) 2016-10-12
MX2021001742A (es) 2021-04-19
AU2020202835A1 (en) 2020-05-21
EP3082826B1 (en) 2020-03-11
AU2020202835B2 (en) 2021-12-02
US20160354394A1 (en) 2016-12-08
US20220241301A1 (en) 2022-08-04
WO2015095793A1 (en) 2015-06-25
JP2020125298A (ja) 2020-08-20
RU2691950C1 (ru) 2019-06-19
MX2016008023A (es) 2017-01-13
RU2016129069A (ru) 2018-01-23
AU2014368971B2 (en) 2020-02-06
KR20160103036A (ko) 2016-08-31
CN114452298A (zh) 2022-05-10
AU2014368971A1 (en) 2016-07-28
US20240299426A1 (en) 2024-09-12
DK3082826T3 (da) 2020-05-04
ES2790703T3 (es) 2020-10-28
IL246146A0 (en) 2016-07-31
EP3082826A4 (en) 2017-08-23
IL246146B1 (en) 2023-11-01
US11337989B2 (en) 2022-05-24
BR112016014506A2 (pt) 2017-10-31
ZA201604862B (en) 2017-08-30
EP3735966A1 (en) 2020-11-11
IL246146B2 (en) 2024-03-01
NZ722215A (en) 2019-02-22
KR102407408B1 (ko) 2022-06-10
JP2022070924A (ja) 2022-05-13
EP3082826A1 (en) 2016-10-26
BR112016014506B1 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
AU2020202835B2 (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
CN100488517C (zh) 捕获和灭活病原性微生物和精子的组合物及其制药用途
JP6738573B2 (ja) 避妊殺菌剤の効果を増強するための組成物および方法
HK40041070A (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
HK1230485B (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
HK1230485A1 (en) Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
HK40021110A (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
OA17704A (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides.
EA041271B1 (ru) Противозачаточная микробицидная композиция и способ предупреждения заболеваний, передающихся половым путем

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107